Does Medicare Advantage Cover Trazodone?

How Medicare Advantage Formularies Classify Trazodone

Most Medicare Advantage plans with integrated Part D benefits place generic trazodone hydrochloride on Tier 1, the preferred generic tier. This is the lowest cost-sharing level available. A smaller number of plans list it on Tier 2. Either placement translates to minimal out-of-pocket spending for enrollees.

The Centers for Medicare & Medicaid Services (CMS) requires every Part D formulary to cover at least two drugs in each therapeutic category. Trazodone belongs to the antidepressant class, specifically the serotonin antagonist and reuptake inhibitor (SARI) subclass, and its generic availability since 1982 makes it one of the cheapest options in the category. CMS formulary reference files for plan year 2025 show trazodone appearing on more than 95% of standalone Part D and Medicare Advantage Prescription Drug (MA-PD) plan formularies nationwide [1].

Generic trazodone is available in 50 mg, 100 mg, 150 mg, and 300 mg tablets. The extended-release formulation (trazodone ER, formerly branded as Oleptro) is less uniformly covered and may sit on Tier 3 or require prior authorization. If your plan covers only immediate-release trazodone, your prescriber can request a formulary exception for the ER version by documenting clinical necessity.

What Copays and Costs to Expect

Your actual copay depends on which Medicare Advantage carrier you enrolled with, your plan's specific benefit design, and which coverage phase you are in. Here is what the numbers typically look like.

During the Initial Coverage Phase, Tier 1 copays for trazodone range from $0 to $10 in most MA-PD plans. Some plans offered through UnitedHealthcare, Humana, Aetna, and BCBS affiliates charge $0 copays for preferred generics through preferred pharmacies. Tier 2 copays, where applicable, run $5 to $15. Once you enter the Coverage Gap (the so-called "donut hole"), you pay no more than 25% of the negotiated price for generic drugs under the Inflation Reduction Act provisions that took full effect in 2025. For a drug averaging $10 per month, that 25% share amounts to roughly $2.50.

The $2,000 annual out-of-pocket cap on Part D spending, effective since January 2025, means trazodone costs are unlikely to cause significant financial strain even if you take multiple other medications. Cash-pay pricing at retail pharmacies averages around $10 for 30 tablets of generic trazodone 50 mg, so even without insurance the drug remains affordable [2].

Prior Authorization: When It Applies and When It Does Not

For the FDA-approved indication of major depressive disorder, prior authorization is uncommon. Most carriers auto-adjudicate trazodone claims at the pharmacy without requiring prescriber documentation.

Three scenarios may trigger a prior authorization request. First, doses exceeding 400 mg per day (the FDA-labeled maximum for depression) can flag quantity-limit edits that require the prescriber to justify the dose [3]. Second, the extended-release formulation often needs prior authorization because plans prefer the cheaper immediate-release version. Third, if a plan has placed trazodone on a non-preferred tier (rare but possible in some regional MA-PD plans), the pharmacy benefit manager may require documentation before dispensing at the preferred copay level.

When prior authorization is triggered, the prescriber submits clinical documentation to the plan. CMS mandates that Part D plans issue a coverage determination within 72 hours for standard requests and 24 hours for expedited requests. The Medicare Prescription Drug Benefit Manual, Chapter 18 outlines these timelines. If the plan does not respond within the required window, the request is deemed approved by default.

Off-Label Use for Insomnia: Coverage Nuances

Trazodone is one of the most prescribed medications for insomnia in the United States, even though the FDA has never approved it for that indication. A 2005 survey published in the Journal of Clinical Psychiatry found that trazodone was the second most commonly prescribed agent for insomnia in the U.S., behind only zolpidem [4]. Prescribers favor low doses (25 to 100 mg at bedtime) because of the drug's sedating antihistaminic and serotonin-2A antagonist properties.

Medicare Part D plans are permitted to cover off-label uses that are supported by recognized compendia. The CMS-accepted compendia include the American Hospital Formulary Service Drug Information (AHFS-DI), DRUGDEX, and Clinical Pharmacology. Trazodone's use for insomnia is listed as a supported off-label indication in AHFS-DI, which means most Part D plans will cover it even when the prescriber writes "insomnia" as the diagnosis code [5].

A potential issue arises if the plan applies utilization management edits tied to diagnosis codes. Some automated systems reject claims linked to ICD-10 code G47.00 (insomnia, unspecified) because the system expects an antidepressant to pair with an F-code (mental health) diagnosis. In these cases, the prescriber can either add a secondary diagnosis of depression or submit a coverage determination request citing the AHFS-DI compendium listing. This is a paperwork issue, not a true coverage exclusion.

Step Therapy Requirements

Step therapy (also called "fail first") policies for trazodone are rare. The drug itself is often used as the first step in insomnia treatment before plans authorize more expensive options like suvorexant (Belsomra) or lemborexant (Dayvigo). In the depression space, plans may require a trial of an SSRI or SNRI before covering certain branded antidepressants, but trazodone, as a low-cost generic, is almost never behind a step therapy wall.

If you encounter a step therapy requirement for trazodone, it is likely a plan-specific anomaly. Your prescriber can request a step therapy exception by demonstrating that the required first-line drug is clinically inappropriate. Acceptable reasons include documented adverse reactions to SSRIs, drug-drug interactions, or a contraindication such as a history of QT prolongation with the first-line agent.

The exception request follows the same timeline as prior authorization: 72 hours for standard review, 24 hours for expedited. CMS regulations at 42 CFR §423.578 guarantee enrollees the right to request exceptions to any utilization management policy, including step therapy.

How to Appeal a Denied Trazodone Claim

A denial does not mean the decision is final. Medicare Part D appeal rights are extensive, and success rates at the first level of appeal are meaningful. CMS data from 2023 showed that approximately 75% of Part D coverage determination requests were decided fully or partially in the enrollee's favor [6].

The appeal process has five levels. Level 1 is a redetermination by the plan itself. You or your prescriber submit a written appeal within 60 days of the denial. The plan must respond within 7 days (standard) or 72 hours (expedited). Level 2 is an independent review by the Medicare Part D Qualified Independent Contractor, currently operated by MAXIMUS Federal Services. You have 60 days to request this review after an unfavorable Level 1 decision. MAXIMUS must decide within 7 days (standard) or 72 hours (expedited).

Level 3 goes before an Administrative Law Judge (ALJ) at the Office of Medicare Hearings and Appeals, available if the amount in controversy meets the annual threshold ($206 for 2025). Level 4 is the Medicare Appeals Council. Level 5 is federal district court review. Most trazodone denials resolve at Level 1 or Level 2.

To strengthen your appeal, include the following: a letter of medical necessity from the prescribing physician, relevant clinical notes or prior medication trials, the AHFS-DI or DRUGDEX compendium citation supporting the indication, and any applicable clinical guidelines. For depression, the American Psychiatric Association's Practice Guideline recognizes trazodone as a treatment option for major depressive disorder [7].

Trazodone for Weight Loss: Why Medicare Will Not Cover It

Some patients and online sources discuss trazodone in the context of weight management, often because the drug is less likely to cause weight gain than mirtazapine or certain SSRIs. Trazodone is not FDA-approved for weight loss, and no major clinical trial has demonstrated significant weight reduction with the drug.

Federal CMS rules specify that Part D plans cannot cover drugs prescribed solely for weight loss or cosmetic purposes. This exclusion, codified in the Social Security Act §1860D-2(e)(2)(A), applies regardless of the drug's other approved indications. If a prescriber writes a trazodone prescription with a weight-loss diagnosis code, the claim will be denied. This denial is not appealable on formulary grounds because the statutory exclusion overrides plan-level formulary decisions.

The March 2024 expansion that allowed Part D coverage of semaglutide (Wegovy) for cardiovascular risk reduction does not create a precedent for trazodone coverage for weight loss. Wegovy's exception was tied to its specific FDA-approved indication for reducing major adverse cardiovascular events in adults with established cardiovascular disease and obesity [8].

Comparing Medicare Advantage Plans for Trazodone Coverage

Not all MA-PD plans are identical, and small differences in benefit design can affect your costs. When comparing plans during the Annual Enrollment Period (October 15 through December 7), check three things.

First, confirm the formulary tier. Use the Medicare Plan Finder to search for trazodone on each plan's formulary. The tool shows the tier, any utilization management restrictions, and the estimated copay at your preferred pharmacy. Second, check the pharmacy network. Plans often offer $0 copays for Tier 1 generics at preferred pharmacies but charge $3 to $10 at standard network pharmacies. Third, review the plan's overall Part D deductible. Some MA-PD plans waive the deductible for generic drugs entirely, meaning you pay only the copay from Day 1. Others apply the standard Part D deductible ($590 in 2025) before copays kick in, though many exempt Tier 1 drugs from this deductible.

If you currently take trazodone and are considering switching Medicare Advantage carriers, run your full medication list through the Medicare Plan Finder. A plan with a $0 trazodone copay but high copays on your other medications may cost more overall than a plan charging $5 for trazodone but offering better coverage for the rest of your regimen.

Quantity Limits and Mail-Order Options

Most Medicare Advantage plans impose quantity limits on trazodone that align with standard prescribing patterns. A typical limit allows 30 tablets per 30 days for doses up to 150 mg, or 60 tablets per 30 days for the 50 mg strength when prescribed at 100 mg daily (two tablets). Quantities exceeding these thresholds require a quantity limit exception.

Mail-order pharmacy benefits offer a cost advantage. Many MA-PD plans provide a 90-day supply for the same copay as a 30-day supply at retail, or for a reduced copay (often two copays for three months of medication). For a stable, chronic prescription like trazodone for depression or insomnia, switching to mail order can cut your annual drug spending for this medication by up to one-third.

Express Scripts, CVS Caremark, and OptumRx operate the mail-order pharmacy networks for most large Medicare Advantage carriers. Check your plan's Evidence of Coverage document for specific mail-order terms. Some plans also permit 90-day fills at preferred retail pharmacies like Costco or Walmart, offering the same extended-supply pricing without requiring mail delivery [9].

Clinical Context: What Trazodone Does and Who Takes It

Trazodone hydrochloride received FDA approval in 1981 for the treatment of major depressive disorder [3]. The drug works primarily by blocking serotonin 5-HT2A receptors and inhibiting serotonin reuptake, a dual mechanism that distinguishes it from SSRIs and SNRIs. At lower doses (25 to 100 mg), the antihistamine H1 and alpha-1 adrenergic receptor blocking properties dominate, producing sedation without the dependence risk associated with benzodiazepines or Z-drugs.

An estimated 25 million trazodone prescriptions are dispensed annually in the United States, making it one of the 50 most prescribed medications in the country [10]. Among Medicare beneficiaries specifically, trazodone prescribing has increased as clinicians look for alternatives to benzodiazepines in older adults. The American Geriatrics Society Beers Criteria lists benzodiazepines and Z-drugs as potentially inappropriate for adults 65 and older, pushing prescribers toward alternatives like trazodone for insomnia management [11].

Common side effects include morning sedation, dizziness, dry mouth, and orthostatic hypotension. Rare but serious risks include priapism (prolonged erection requiring emergency treatment, reported in fewer than 1 in 10,000 patients) and cardiac arrhythmias at high doses. The Mendelson 2005 review in the Journal of Clinical Psychiatry examined trazodone's risk-benefit profile for insomnia and concluded that low-dose use (50 to 100 mg) carries a favorable safety margin in adults without significant cardiac disease [4].

Trazodone should be taken with food to improve absorption and reduce dizziness. Prescribers typically start at 150 mg per day in divided doses for depression, titrating up to 400 mg per day (outpatient maximum) based on response. For insomnia, the starting dose is usually 25 to 50 mg at bedtime.